Key Highlights
● The biotech ETF jumped, outpacing the S&P 500.
● Quantum-Si jumped to $1.60 after a protein-sequencing update.
● Illumina and 10x Genomics rose without company-specific news.
● Volume was light at 14.37 billion shares.
The iShares Biotechnology ETF holds a basket of large and mid-sized drug developers and life-science tools companies, so it offers a quick read on sentiment across the whole sector. On Friday, that read was emphatic: the fund jumped, outpacing the S&P 500, which rose 46.18 points to 7,811.54.
The gain was notable for its breadth. Instead of one or two heavyweights carrying the fund, buying showed up across vaccines, genomics tools, gene editing and protein research.
The vaccine spark
The catalyst was a report that the National Institutes of Health is planning a public-private initiative to fast-track cancer vaccine research starting in December. Moderna (NASDAQ:MRNA) soared $28.00 to $225.00, its highest level since 2021, and joined the Nasdaq-100 the same morning. BioNTech, Novavax, Arcturus and Vaxcyte also rallied.
Large biotech names helped too. Amgen (NASDAQ:AMGN) climbed to about $414.87 and Gilead rose, though neither had company-specific news.
Tools and genomics
Companies that sell equipment and services to drug developers moved strongly. Illumina (NASDAQ:ILMN), the leading maker of gene sequencing machines, climbed without company-specific news. 10x Genomics (NASDAQ:TXG) jumped to about $84.09 during the session, and Twist Bioscience (NASDAQ:TWST) rose to about $165.19. Ginkgo Bioworks rallied after saying it will offer access to its autonomous Boston lab for a National Science Foundation programme.
These businesses tend to benefit when research budgets and drug pipelines expand, so a federal push on cancer vaccines can be read as positive for them too.
Protein sequencing gets a boost
One of the more striking moves came from Quantum-Si (NASDAQ:QSI), which jumped to $1.60 after saying its Proteus platform can now identify 19 of the 20 amino acids. Chief executive Jeff Hawkins called the result "an important step toward our goal" of detecting all 20 by the end of 2026. Peer Nautilus Biotechnology (NASDAQ:NAUT) also surged without same-day news of its own. Both are low-priced shares that can swing sharply in both directions.
Gene-editing developer Prime Medicine (NASDAQ:PRME) climbed to about $4.01, and antibody-discovery company Absci (NASDAQ:ABSI) rose to about $10.14, both without company-specific news. ImmunityBio (NASDAQ:IBRX), which focuses on cancer immunotherapy, gained to about $10.60.
Why rates still matter
Biotech is often seen as sensitive to interest rates, because many companies are years away from profits and rely on outside funding. That makes Friday's rally more notable: the 10-year Treasury yield remains near a 24-year high, and the Fed raised rates in September for the first time since 2023, with Governor Christopher Waller saying more hikes are likely. The sector's strength suggests investors were focused on news flow rather than borrowing costs, at least for one day.
Health care finished among the best S&P 500 sectors on Friday and was one of the strongest groups for the week. Across the market, NYSE advancers beat decliners by about 1.65 to 1, though volume on US exchanges was light at 14.37 billion shares against a 20-day average of 17.76 billion.
Wednesday's CPI Could Shift the Rate Path That Biotech Relies On
Investors will look for formal NIH details on the cancer-vaccine initiative ahead of December. September consumer prices on Wednesday, October 14 could shift rate expectations, which matter for biotech funding. Johnson & Johnson (NYSE:JNJ) reports Tuesday, October 13. Stock exchanges stay open on Monday, October 12, though the bond market observes Columbus Day. The Fed meets October 27–28.






Please wait processing your request...